Pascal Deschatelets, Ph.D
ADVISOR
Dr. Deschatelets specializes in commercializing research successfully. He has been founder of three start-ups that have successfully raised over $70M . He has successfully developed drug candidates from academic labs up to phase 2 clinical trials in multiple countries.
Pascal is the co-founder and the Chief Operating Officer Apellis Pharmaceuticals, a company developing peptide inhibitors of the complement system for a wide range of diseases including COPD and paroxysmal nocturnal hemoglobinuria. Prior to founding Apellis, Pascal founded Potentia Pharmaceuticals, a company focused on the development of peptide drugs for ocular diseases such as age-related macular degeneration. Dr. Deschatelets was also a co-founder of Syntetica Fine Chemicals, a custom chemical synthesis company supporting the pharmaceutical industry, Revon Systems, an Health IT company supporting clinical trial recruitment and monitoring, and Liberate Medical, a medical device company.
Dr. Deschatelet’score experience lies in taking early stage drug candidates through various stages of development and managing operations of increasing complexity. He has substantial experience across various life science sectors that include preclinical toxicology, early stage regulatory, manufacturing, analytical, formulation and drug delivery.
Dr. Deschatelets received his Ph.D. in organic chemistry from the University of Montreal and his post-doctoral training in the laboratory of Dr. George Whitesides at Harvard University. He has extensive experience in developing new drug candidates from bench to bedside but has also a particular interesting in nanobiotechnology, drug delivery, and in the synthesis of organic molecules and bioconjugates.
